

ARRAY BIOPHARMA INC  
Form 8-K  
November 30, 2010

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 30, 2010

**Array BioPharma Inc.**

(Exact name of registrant as specified in its charter)

Colorado

000-31979

84-1460811

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

3200 Walnut Street, Boulder, Colorado

80301

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(303) 381-6600

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Top of the Form**

**Item 8.01 Other Events.**

On November 30, 2010, Array BioPharma Inc. issued a press release announcing that a \$10 million clinical research milestone was achieved in its collaboration with Celgene Corporation. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 - Press release dated November 30, 2010 entitled "ARRAY BIOPHARMA ACHIEVES CLINICAL MILESTONE IN CELGENE COLLABORATION."

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Array BioPharma Inc.

*November 30, 2010*

By: *R. Michael Carruthers*

---

*Name: R. Michael Carruthers  
Title: Chief Financial Officer*

---

Edgar Filing: ARRAY BIOPHARMA INC - Form 8-K

**Top of the Form**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated November 30, 2010 entitled "ARRAY BIOPHARMA ACHIEVES CLINICAL MILESTONE IN CELGENE COLLABORATION."